作者对31例雷诺氏综台征患者进行了24周的双盲安慰剂对照交叉试验。患者男性10例,女性21例,平均年龄45.2岁(19～70岁)。20例诊为雷诺氏病,11例为雷诺氏综合征伴有结缔组织疾病。在进入研究时该综合征的病期为2～44年(平均7.7年)。研究前8周患者停止任何有关雷诺氏综合征的药物治疗。患者用α阻滞剂—苯氧苄胺,每天10～20毫克分二次口服,以及联合应用α阻滞剂苯氧苄胺, The authors conducted a double-blind placebo-controlled crossover trial of 31 patients with Renault’s syndrome over a 24-week period. There were 10 males and 21 females, with an average age of 45.2 years (19-70 years). 20 cases were diagnosed as Raynaud’s disease and 11 cases were associated with Renal’s syndrome with connective tissue disease. The syndrome had a disease duration of 2 to 44 years (mean, 7.7 years) at study entry. Patients discontinued any medication related to Raynaud’s syndrome 8 weeks prior to the study. Patients with α blockers - phenoxybenzamine, 10 to 20 mg orally twice daily orally, and the combination of α-blocker phenoxybenzamine,